Estudo randomizado | Tofacitinibe (medicamento de uso oral) mostrou ser eficaz em pacientes com artrite idiopática juvenil de curso poliarticular.
22 Nov, 2021 | 09:07hTofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial – The Lancet (link para o resumo – $ para o texto completo)
Comentário no Twitter
NEW in @TheLancet — Tofacitinib in juvenile idiopathic #arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
Flare rate by week 44 was significantly lower with tofacitinib (29%) than with placebo (53%) https://t.co/28JRrbPf8e #JIA pic.twitter.com/JzxHLNmgym
— The Lancet Rheumatology (@TheLancetRheum) November 10, 2021